The PARPi with the highest PARP trapping activity, talazoparib and niraparib, were found to be most effective in increasing the cytotoxicity of cisplatin in bladder cancer cells (Bhattacharjee et al., 2022). Here, PARP1 is linked to urinary bladder cancer.